PPADS (sodium salt) – 50 mg

Brand:
Cayman
CAS:
192575-19-2
Storage:
-20
UN-No:
Non-Hazardous - /

P2X and P2Y purinergic receptors are ATP-sensitive receptors responsible for mediating a large variety of excitatory postsynaptic responses including fast transmission at central synapses, contraction of smooth muscle cells, platelet aggregation, macrophage activation, and apoptosis. PPADS is a non-selective P2 purinergic antagonist that blocks recombinant P2X1-5 (IC50s = 1-2.6 μM), native P2Y2-like (IC50 = ~0.9 mM), and recombinant P2Y4 (IC50 = ~15 mM) receptors.{22825} PPADS antagonism of ATP-sensitive P2 receptors produces neuroprotective effects in an ischemia model with permanent middle cerebral artery occlusion in spontaneously hypertensive rats.{22824}  

 

SKU: - Category:

Description

A non-selective P2 purinergic antagonist that blocks recombinant P2X1-5 (IC50s = 1-2.6 μM), native P2Y2-like (IC50 = ~0.9 mM), and recombinant P2Y4 (IC50 = ~15 mM) receptors; produces neuroprotective effects in an ischemia model with permanent middle cerebral artery occlusion in spontaneously hypertensive rats


Formal name: 4-[2-[4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-2-pyridinyl]diazenyl]-1,3-benzenedisulfonic acid, tetrasodium salt

Synonyms:  Pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid

Molecular weight: 599.3

CAS: 192575-19-2

Purity: ≥95%

Formulation: A solid


Product Type|Biochemicals|Ion Channel Modulation|Blockers||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Cardiovascular Diseases|Stroke||Research Area|Neuroscience|Neuroprotection|Ischemia